Liraglutide antidiabetic drugs
systematic review meta-analysis network meta-analysis
 

victoza - liraglutide      

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultcardiovascular eventsHbA1c

diabetes type 2  

NN2211-1333     liraglutide other doses -
Pratley (1.8 vs 1.2), 2010   liraglutide 1.8mgliraglutide 1.2mgnegative 0%
LEADER, 2016      NCTliraglutideplaceboLow risk of bias conclusive-12%
NN2211-1571 (Vilsbøll), 2007        NCTliraglutide other dosesplaceboExploratory negative
Seino, 2008      NCTliraglutide other dosesplaceboExploratory negative
Madsbad (vs placebo), 2004     liraglutide other dosesplacebonegative
Harder, 2004     liraglutide other dosesplaceboExploratory -
Kaku 0.6mg, 2010     liraglutide other dosesplaceboLow risk of bias suggesting
LEAD-2 (Nauck) (1.2mg vs placebo), 2009        NCTliraglutide 1.2mgplacebo (add on MET)Low risk of bias suggesting
LEAD-2 (Nauck) (1.8mg vs placebo), 2009      NCTliraglutide 1.8mgplacebo (add on MET)Low risk of bias suggesting
NN2211-1796      NCTliraglutide other dosesplacebo (add on MET) -
LEAD-1 SU (1.2 mg vs placebo), 2009        NCTliraglutide 1.2mgplacebo (add on SU)Low risk of bias suggesting
LEAD-1 SU (1.8 mg vs placebo), 2009      NCTliraglutide 1.8mgplacebo (add on SU)Low risk of bias suggesting
LEAD-5 (vs placebo), 2009      NCTliraglutide 1.8mgplacebo (add on SU+MET)Low risk of bias suggesting 148%
LEAD-4 (1.2mg), 2009      NCTliraglutide 1.2mgplacebo (add on TZD+MET)Low risk of bias suggesting24%
LEAD-4 (1.8mg), 2009      NCTliraglutide 1.8mgplacebo (add on TZD+MET)Low risk of bias suggesting-25%
Kaku 0.9mg, 2010     liraglutide other dosesplacebo (on top SU)Low risk of bias suggesting
LEAD-6, 2009        NCTliraglutide 1.8mgexenatide on top MET/SU/MET+SURisk of bias suggesting
Seino, 2010      NCTliraglutide other dosesglibenclamideLow risk of bias negative
LEAD-3 mono 1.2mg (Garber), 2009          NCTliraglutide 1.2mgglimepirideLow risk of bias negative
LEAD-3 mono 1.8mg (Garber), 2009      NCTliraglutide 1.8mgglimepirideLow risk of bias negative
Madsbad (vs Glimepiride), 2004     liraglutide other dosesglimepirideExploratory suggesting
LEAD-2 (Nauck) (1.2 mg vs glimepiride), 2009        NCTliraglutide 1.2mgglimepiride (add on MET)Low risk of bias negative
LEAD-2 (Nauck) (1.8 mg vs glimepiride), 2009      NCTliraglutide 1.8mgglimepiride (add on MET)Low risk of bias negative
LEAD-5 (vs Glargine), 2009    NCTliraglutide 1.8mginsulin glargine (add on SU+MET)Risk of bias negative
LEAD 1 (1.8 vs 1.2), 2009   liraglutide 1.8mgliraglutide 1.2mgnegative
LEAD 2 (1.8 vs 1.2), 2009   liraglutide 1.8mgliraglutide 1.2mgnegative
LEAD 4 (1.8 vs 1.2), 2009   liraglutide 1.8mgliraglutide 1.2mgnegative
Feinglos, 2005     liraglutide other dosesmetforminExploratory negative
LEAD-1 SU (1.2 vs rosiglitazone), 2009   liraglutide 1.2mgrosiflitazonesuggesting
LEAD-1 SU (1.8 vs rosiglitazone), 2009      NCTliraglutide other dosesrosiglitazone (add on SU)Low risk of bias suggesting
Pratley 1.2mg, 2010      NCTliraglutide 1.2mgsitagliptinRisk of bias suggesting -3%
Pratley 1.8mg, 2010    NCTliraglutide 1.8mgsitagliptinLow risk of bias suggesting -3%

obesity and overweight  

Astrup (NN8022-1807 ), 2009    NCTliraglutideplaceboLow risk of bias -



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons